These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38395389)

  • 1. Characterization of the plasma proteomic profile of Fabry disease: Potential sex- and clinical phenotype-specific biomarkers.
    López-Valverde L; Vázquez-Mosquera ME; Colón-Mejeras C; Bravo SB; Barbosa-Gouveia S; Álvarez JV; Sánchez-Martínez R; López-Mendoza M; López-Rodríguez M; Villacorta-Argüelles E; Goicoechea-Diezhandino MA; Guerrero-Márquez FJ; Ortolano S; Leao-Teles E; Hermida-Ameijeiras Á; Couce ML
    Transl Res; 2024 Jul; 269():47-63. PubMed ID: 38395389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Globotriaosylsphingosine (Lyso-Gb
    Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
    J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early markers of Fabry disease revealed by proteomics.
    Matafora V; Cuccurullo M; Beneduci A; Petrazzuolo O; Simeone A; Anastasio P; Mignani R; Feriozzi S; Pisani A; Comotti C; Bachi A; Capasso G
    Mol Biosyst; 2015 Jun; 11(6):1543-51. PubMed ID: 25666440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
    Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
    Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Beta 2-Microglobulin, Cystatin C, and Lipocalin-2 as Renal Biomarkers for Patients with Fabry Disease.
    Braga MC; Fonseca FLA; Marins MM; Gomes CP; Bacci MR; Martins AM; D'Almeida V
    Nephron; 2019; 143(4):217-227. PubMed ID: 31216546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.
    Cigna D; D'Anna C; Zizzo C; Francofonte D; Sorrentino I; Colomba P; Albeggiani G; Armini A; Bianchi L; Bini L; Duro G
    Mol Biosyst; 2013 Jun; 9(6):1162-8. PubMed ID: 23385635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
    Talbot A; Nicholls K; Fletcher JM; Fuller M
    Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
    Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
    Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
    Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
    Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
    BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.
    Olivera S; Iñiguez C; García-Fernández L; Sierra JL; Camón AM; Menao S; Torralba MÁ
    Mult Scler Relat Disord; 2020 Feb; 38():101466. PubMed ID: 31715500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.
    Alharbi FJ; Baig S; Rambhatla SB; Vijapurapu R; Auray-Blais C; Boutin M; Steeds R; Wheeldon N; Dawson C; Geberhiwot T
    Clin Chim Acta; 2020 Jan; 500():120-127. PubMed ID: 31654629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidental finding of cornea verticillata or lamellar inclusions in kidney biopsy: measurement of lyso-Gb3 in plasma defines between Fabry disease and drug-induced phospholipidosis.
    Politei J; Frabasil J; Durand C; Di Pietrantonio S; Fernandez A; Albertón V; Velasquez Rivas D; Barriales-Villa R; Larrañaga-Moreira J; Schenone AB
    Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165985. PubMed ID: 33022387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Cardiac Involvement in Fabry Disease (FD) with Native T1 Mapping.
    Roller FC; Fuest S; Meyer M; Harth S; Gündüz D; Bauer P; Schneider C; Rolfs A; Krombach GA; Tanislav C
    Rofo; 2019 Oct; 191(10):932-939. PubMed ID: 30754056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
    Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
    PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.
    Nowak A; Mechtler T; Kasper DC; Desnick RJ
    Mol Genet Metab; 2017 Aug; 121(4):320-324. PubMed ID: 28663131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease.
    Hollander Z; Dai DL; Putko BN; Yogasundaram H; Wilson-McManus JE; Thompson RB; Khan A; West ML; McManus BM; Oudit GY
    Eur J Heart Fail; 2015 Mar; 17(3):291-300. PubMed ID: 25619383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and platelet lipidome changes in Fabry disease.
    Burla B; Oh J; Nowak A; Piraud N; Meyer E; Mei D; Bendt AK; Studt JD; Frey BM; Torta F; Wenk MR; Krayenbuehl PA
    Clin Chim Acta; 2024 Aug; 562():119833. PubMed ID: 38955246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
    Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.